Evidence map›Paper›PMID 34144715›Full record

ArticleBMC medicine2021

Using syndromic measures of mortality to capture the dynamics of COVID-19 in Java, Indonesia, in the context of vaccination rollout.

Bimandra A Djaafara, Charles Whittaker, Oliver J Watson, Robert Verity, Nicholas F Brazeau, Widyastuti, Dwi Oktavia, Verry Adrian, Ngabila Salama, Sangeeta Bhatia and 13 more

Abstract read
In one paragraph

Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Estimating national excess mortality from subnational data: application to Argentina.Revista panamericana de salud publica = Pan American journal of public health · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Bimandra A DjaafaraMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK. bimandra.djaafara15@imperial.ac.uk.ORCID 0000-0001-7481-2624
Charles WhittakerMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Oliver J WatsonMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Robert VerityMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Nicholas F BrazeauMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
WidyastutiJakarta Provincial Department of Health, Jakarta, Indonesia.
Dwi OktaviaJakarta Provincial Department of Health, Jakarta, Indonesia.
Verry AdrianJakarta Provincial Department of Health, Jakarta, Indonesia.
Ngabila SalamaJakarta Provincial Department of Health, Jakarta, Indonesia.
Sangeeta BhatiaMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Pierre NouvelletMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Ellie Sherrard-SmithMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Thomas S ChurcherMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Henry SurendraEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Rosa N LinaEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Lenny L EkawatiEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Karina D LestariEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Adhi AndriantoEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Guy ThwaitesOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
J Kevin BairdEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Azra C GhaniMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Iqbal R F ElyazarEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Patrick G T WalkerMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London St Mary's Campus, Norfolk Place, London, W2 1PG, UK.

Funding

Medical Research Council MC_PC_19012Medical Research Council MR/R015600/1Wellcome TrustWellcome Trust 106680/Z/14/ZWellcome Trust 110179/Z/15/ZWellcome Trust 221350/Z/20/Z
6 · The paper itself

Abstract

backgroundAs in many countries, quantifying COVID-19 spread in Indonesia remains challenging due to testing limitations. In Java, non-pharmaceutical interventions (NPIs) were implemented throughout 2020. However, as a vaccination campaign launches, cases and deaths are rising across the island.

methodsWe used modelling to explore the extent to which data on burials in Jakarta using strict COVID-19 protocols (C19P) provide additional insight into the transmissibility of the disease, epidemic trajectory, and the impact of NPIs. We assess how implementation of NPIs in early 2021 will shape the epidemic during the period of likely vaccine rollout.

resultsC19P burial data in Jakarta suggest a death toll approximately 3.3 times higher than reported. Transmission estimates using these data suggest earlier, larger, and more sustained impact of NPIs. Measures to reduce sub-national spread, particularly during Ramadan, substantially mitigated spread to more vulnerable rural areas. Given current trajectory, daily cases and deaths are likely to increase in most regions as the vaccine is rolled out. Transmission may peak in early 2021 in Jakarta if current levels of control are maintained. However, relaxation of control measures is likely to lead to a subsequent resurgence in the absence of an effective vaccination campaign.

conclusionsSyndromic measures of mortality provide a more complete picture of COVID-19 severity upon which to base decision-making. The high potential impact of the vaccine in Java is attributable to reductions in transmission to date and dependent on these being maintained. Increases in control in the relatively short-term will likely yield large, synergistic increases in vaccine impact.

Indexed as

COVID-19COVID-19 VaccinesHumansImmunization ProgramsIndonesiaSARS-CoV-2SyndromeVaccinationCOVID-19 VaccinesCOVID-19IndonesiaModellingNon-pharmaceutical interventionsSurveillanceVaccinations

Identifiers

PMID34144715
PMCPMC8212796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.